Completely agree after having invested in some patent infringement cases. STSI's tobacco manufacturing patents are also a case in point. What did STSI get in the end after a decade of litigation. The risk of a work-around for manufacturing patents is always high.
For more beneficial for STSI would be approval for the "use" patent. This is when I believe that pharma interest will really start to open up.
News 
Market Data 
Discover 
AI
